--- title: "ABVC BioPharma | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/277679873.md" datetime: "2026-03-03T21:26:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277679873.md) - [en](https://longbridge.com/en/news/277679873.md) - [zh-HK](https://longbridge.com/zh-HK/news/277679873.md) --- # ABVC BioPharma | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -0.39. EBIT: As of FY2025, the actual value is USD -6.902 M. ABVC BioPharma, Inc. operates as a single reportable segment. The company did not generate any revenue for the year ended December 31, 2025, which is a -100% decrease from $509,589 in 2024. Gross profit also decreased by -100% from $508,826 in 2024 to $0 in 2025. #### Operational Metrics - Total operating expenses increased by 37% to $7,151,259 in 2025, from $5,214,068 in 2024, primarily due to higher stock-based compensation expenses for consulting services and rent. - Selling, General and Administrative Expenses were $2,887,358 in 2025, up from $2,261,336 in 2024. - Research and Development Expenses were $121,085 in 2025, down from $179,272 in 2024. - Stock-based Compensation amounted to $4,142,816 in 2025, an increase from $2,773,460 in 2024. - Loss from Operations increased by 52% to - $7,151,259 in 2025, from - $4,705,242 in 2024. - Total Other Expense, Net, was - $1,201,546 in 2025, an 81% increase in expense from - $664,334 in 2024, mainly due to an impairment loss on an equity investment. - Interest Income was $167,103 in 2025, up from $87,358 in 2024. - Interest Expense was - $415,890 in 2025, a 66% decrease from - $825,899 in 2024. - Loss on Investment in Equity Securities was - $192,759 in 2025, compared to - $339,171 in 2024. - Loss on Impairment of Equity Investment was - $803,008 in 2025, with no comparable loss in 2024. - The Net Loss for 2025 was - $8,376,959, a 59% increase from - $5,259,037 in 2024, attributed to increased engagement of consultants. #### Liquidity and Capital Resources - The Working Capital Deficit was - $3,662,633 as of December 31, 2025, an improvement from - $4,377,646 as of December 31, 2024. - Cash Flow Used in Operating Activities was - $2,986,299 in 2025, a 65% increase in outflow from - $1,809,145 in 2024, mainly due to increased operating expenses. - Cash Flow Used in Investing Activities was - $1,208,790 in 2025, compared to $0 in 2024, primarily due to an increase in loans to related parties which were fully repaid in February 2026. - Cash Flow Provided by Financing Activities was $4,637,995 in 2025, a 134% increase from $1,980,769 in 2024, mainly from private placements, warrant exercises, and convertible notes issuance. - Cash and Cash Equivalents were $681,480 as of December 31, 2025, compared to $248,382 as of December 31, 2024. - Restricted Cash was $645,505 as of December 31, 2025, compared to $615,433 as of December 31, 2024. #### Outlook / Guidance ABVC BioPharma, Inc. plans to advance ABV-1701 Vitargus® to its pivotal trial phase, anticipating future revenues. The company also intends to license ABV-1504 for Major Depressive Disorder following successful Phase II completion and to complete Phase II, Part 2 clinical trials for ABV-1505 for Attention Deficit Hyperactivity Disorder. The overarching strategy involves out-licensing drug and medical device candidates to major pharmaceutical companies for later-stage clinical trials and subsequent marketing upon regulatory approval. ### Related Stocks - [ABVC.US](https://longbridge.com/en/quote/ABVC.US.md) ## Related News & Research - [US strategic oil reserve hits lowest level since 2024 amid record draw](https://longbridge.com/en/news/286956962.md) - [Kohl’s approves 2024 Long-Term Compensation Plan, extends term and increases share authorization](https://longbridge.com/en/news/287276077.md) - [FOCUS-As cocoa prices melt down, real chocolate is making a comeback](https://longbridge.com/en/news/287091302.md) - [Seacor Marine Modifies 2024 Credit Deal; Frees $13.7M Escrow, Cancels $24.6M Tranche B](https://longbridge.com/en/news/287274264.md) - [EchoStar draws investor focus as SpaceX IPO nears](https://longbridge.com/en/news/287251831.md)